Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases, and more particularly, to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases containing, as active ingredients, any one or two or more compounds selected from a group consisting of the compound of chemical formula 1, the compound of chemical formula 2, and the acceptable salts thereof. The pharmaceutical composition repairs nerve tissue damaged by herpes zoster to reduce the acute pain caused by herpes zoster, prevents postherpetic neuralgia, and enables a fundamental treatment through the recovery of nerve tissue in the postherpetic neuralgia. Further, the pharmaceutical composition can be effectively used for neuronal damage, including sciatic nerve crushing damage or the like, in a neuropathy including diabetic neuropathy or the like and for neuropathic pain, as well as for a variety of diseases caused by nerve tissue damage, such as brain diseases including strokes or the like.

1 . A pharmaceutical composition for preventing or treating neuronal damage and neurological disease, the pharmaceutical composition comprising as an active ingredient at least one compound selected from the group consisting of a compound represented by Formula 1 below, a compound represented by Formula 2 below, and an available salt thereof: 
       
         
           
           
               
               
           
         
         in Formula 1, X is OH, SH or O − , R 1 , R 2 , and R 3  are each a linear or cyclic alkyl, alkenyl or alkynyl, —C(═O)R 4 , —(CH 2 )nOH, —(CH 2 )nNR 5 R 6 , —(CH 2 )nN + R 7 R 8 R 9 , —CH 2 CH(COOH)NH 2 , —CH 2 CH(COO − )NH 2 , —CH 2 CH(COOH)NH 3   + , inositol, pentose, hexose, glycerol, phosphatidyl glycerol, or H, n is an integer of 1 to 10, and R 4 , R 5 , R 6 , R 7 , R 8 , and R 9  are each a linear or cyclic alkyl, alkenyl or alkynyl, or H, and 
       
       
         
           
           
               
               
           
         
         in Formula 2, R 1 , R 2 , R 3 , R 4 , and R 5  are each a linear or cyclic alkyl, alkenyl or alkynyl, —C(═O)R 6 , phosphocholine, phosphoric acid, pentose, hexose or a derivative of these saccharides, an amino sugar, an alkoxy phosphoric acid, or H, and R 6  is a linear or cyclic alkyl, alkenyl, or alkynyl. 
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the compound is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, phosphatidylinositols, phosphatidic acids, sphingophospholipids, sphingomyelins, plasmalogens, sphingoplasmalogens, phosphatidyl glycerol, cardiolipins, cerebrosides, ceramides, lyso-type materials thereof and available salts thereof. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the neuronal damage and neurological disease are selected from the group consisting of damage of peripheral nerves, damage of central nerves, neuropathy, neuropathic pain, and cerebropathy. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the neuropathy or neuropathic pain is selected from the group consisting of acute inflammatory demyelinating peripheral polyneuropathy, chronic inflammatory demyelinating peripheral polyneuropathy, diabetic peripheral neuropathy, herpes zoster, vasculitis neuropathy, hereditary peripheral neuropathy, spino cerebellar degeneration, amyotrophic lateral sclerosis, painful diabetic peripheral neuropathy, trigeminal neuralgia, carcinomatous neuro-pathy occurring along cerebral cortex or spinothalamic tract, post-traumatic neuropathy, post-herpetic neuralgia, phantom limb pain, post-stroke central pain, and thalamic pain. 
     
     
         5 . The pharmaceutical composition of  claim 3 , wherein the neuropathy or neuropathic pain is selected from the group consisting of diabetic peripheral neuropathy, herpes zoster, vasculitis neuropathy, painful diabetic peripheral neuropathy, trigeminal neuralgia, post-traumatic neuropathy, post-herpetic neuralgia, and phantom limb pain. 
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the neuropathy or neuropathic pain is selected from the group consisting of herpes zoster and post-herpetic neuralgia. 
     
     
         7 . The pharmaceutical composition of  claim 3 , wherein the cerebropathy is selected from the group consisting of stroke, brain tumor, dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and ischemic cerebropathy. 
     
     
         8 . The pharmaceutical composition of  claim 3 , wherein the damage of peripheral nerves or damage of central nerves is selected from the group consisting of neurotmesis and traumatic neuronal damage. 
     
     
         9 . The pharmaceutical composition of  claim 1 , further comprising at least one selected from the group consisting of vegetable gel, a vegetable resin, or a synthetic resin. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the vegetable gel, vegetable resin, or synthetic resin is selected from the group consisting of aloe gel; a seaweed extract selected from the group consisting of kelp extract, agar extract, and Fucoidan; a vegetable or synthetic resin that functions like the foregoing; and a mixture thereof. 
     
     
         11 . The pharmaceutical composition of  claim 9 , wherein the pharmaceutical composition comprises 0.1 to 99.9 wt % of the at least one compound selected from the group consisting of the compound represented by Formula 1, the compound represented by Formula 2, and an available salt thereof and 0.1 to 99.9 wt % of the at least one selected from the group consisting of a vegetable gel, a vegetable resin, and a synthetic resin. 
     
     
         12 . The pharmaceutical composition of  claim 2 , wherein the neuronal damage and neurological disease are selected from the group consisting of damage of peripheral nerves, damage of central nerves, neuropathy, neuropathic pain, and cerebropathy. 
     
     
         13 . The pharmaceutical composition of  claim 2 , further comprising at least one selected from the group consisting of vegetable gel, a vegetable resin, or a synthetic resin.